These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19309535)

  • 1. MAOA is associated with methylphenidate improvement of oppositional symptoms in boys with attention deficit hyperactivity disorder.
    Guimarães AP; Zeni C; Polanczyk G; Genro JP; Roman T; Rohde LA; Hutz MH
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):709-14. PubMed ID: 19309535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.
    Salatino-Oliveira A; Genro JP; Zeni C; Polanczyk GV; Chazan R; Guimarães AP; Callegari-Jacques SM; Rohde LA; Hutz MH
    Biol Psychiatry; 2011 Aug; 70(3):216-21. PubMed ID: 21550019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-gene interaction between COMT and MAOA potentially predicts the intelligence of attention-deficit hyperactivity disorder boys in China.
    Qian QJ; Yang L; Wang YF; Zhang HB; Guan LL; Chen Y; Ji N; Liu L; Faraone SV
    Behav Genet; 2010 May; 40(3):357-65. PubMed ID: 19941049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender Differences in the Behavioral Symptoms and Neuropsychological Performance of Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate: A Two-Year Follow-up Study.
    Wang LJ; Chen CK; Huang YS
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):501-8. PubMed ID: 26262904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Monoamine Oxidase A (MAOA) Gene uVNTR and rs6323 Polymorphisms with Attention Deficit and Hyperactivity Disorder in Korean Children.
    Hwang IW; Lim MH; Kwon HJ; Jin HJ
    Medicina (Kaunas); 2018 May; 54(3):. PubMed ID: 30344263
    [No Abstract]   [Full Text] [Related]  

  • 8. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
    Wang LJ; Chen CK; Huang YS
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
    Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH
    Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.
    Tzang RF; Wang YC; Yeh CB; Hsu CD; Liang HY; Yang PC; Liu HJ; Huang YS; Cheng H; Hsu YC; Liu SI; Pan CH; Huang YF; Huang CF; Wu YY; Huang YH; Liu HC; Chang HL
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):53-63. PubMed ID: 22250610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
    Abikoff H; Nissley-Tsiopinis J; Gallagher R; Zambenedetti M; Seyffert M; Boorady R; McCarthy J
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):166-75. PubMed ID: 19127171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study.
    Bruxel EM; Salatino-Oliveira A; Akutagava-Martins GC; Tovo-Rodrigues L; Genro JP; Zeni CP; Polanczyk GV; Chazan R; Schmitz M; Arcos-Burgos M; Rohde LA; Hutz MH
    Genes Brain Behav; 2015 Jun; 14(5):419-27. PubMed ID: 25989180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD.
    da Silva BS; Cupertino RB; Rovaris DL; Schuch JB; Kappel DB; Müller D; Bandeira CE; Victor MM; Karam RG; Mota NR; Rohde LA; Contini V; Grevet EH; Bau CHD
    Mol Psychiatry; 2018 Jun; 23(6):1446-1452. PubMed ID: 28461697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity.
    Wargelius HL; Malmberg K; Larsson JO; Oreland L
    Psychiatr Genet; 2012 Feb; 22(1):42-5. PubMed ID: 21610556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
    Yılmaz S; Bilgiç A; Hergüner S
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
    Kim E; Cheon KA; Joung YS; Kim JY; Song DH
    Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2013; 36(5):141-5. PubMed ID: 24045603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.